Posted: 17 October 2025
Chimeric Therapeutics (ASX:CHM) has signed a Letter of Intent (LOI) with Viral Vector Manufacturing Facility Pty Ltd (VVMF) to establish a strategic partnership focused on the development and Good Manufacturing Practice (GMP) production of Lentiviral vectors in Australia.
Under the agreement, VVMF will support process development, technology transfer and GMP-grade manufacturing of Lentiviral vectors for Chimeric’s clinical-stage chimeric antigen receptor T-cell (CAR-T) therapy programme. Viral vectors are essential in producing CAR-T therapies, which are revolutionising cancer treatment worldwide.
“We’re pleased to partner with VVMF as we continue to advance our CAR-T cell therapy programmes,” said Chimeric Therapeutics CEO Dr Rebecca McQualter. “Having access to local, GMP-grade viral vector manufacturing not only strengthens our supply chain but also supports the broader goal of building world-class advanced therapy capabilities here in Australia.”
VVMF CEO Stephen Thompson said the collaboration would strengthen sovereign manufacturing and create high-value jobs in Western Sydney. “This collaboration allows us to demonstrate our capability to develop and manufacture GMP-grade viral vectors for the global cell and gene therapy marketplace,” he said.
The agreement was described as a milestone for Australia’s growing advanced manufacturing sector and the development of Advanced Therapy Medicinal Products (ATMPs) — innovative medicines derived from genes, cells, or engineered tissues. These therapies are opening new possibilities for treating cancer, neurodegenerative, and cardiovascular diseases.
Supported by strong R&D incentives, a pragmatic regulatory environment and a mature clinical trial ecosystem, Australia is well positioned to become a global hub for advanced therapy development and manufacturing.
Find out more here.
